Promiscuous Expression of H2B-GFP Transgene in Hematopoietic Stem Cells by Challen, Grant A. & Goodell, Margaret A.
Promiscuous Expression of H2B-GFP Transgene in
Hematopoietic Stem Cells
Grant A. Challen
1,2, Margaret A. Goodell
1*
1Center For Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, United States of America, 2Monash University, Clayton, Victoria, Australia
Abstract
Background: The study of adult stem cells relies on the ability to isolate them using complex combinations of markers for
flow cytometry. A recent study has used a tetracycline-regulatable H2B-GFP transgenic mouse model analogous to BrdU
pulse-chase methods to fluorescently label quiescent skin stem cells in vivo. In this study, we sought to use these mice to
fluorescently label hematopoietic stem cells to study niche interactions.
Methods and Findings: We crossed the H2B-GFP mice to mice carrying a tetracycline-regulated transactivator protein.
When these mice were administered doxycycline, we observed a gradual decrease in total bone marrow GFP
+ cells over
12 weeks but the hematopoietic stem cell population remained largely GFP
+ (.85%). In histological bone sections, the
long-term GFP label-retaining cells tended to concentrate at the endosteal surface and competitive transplantation assays
showed that the majority of hematopoietic stem cell activity was contained in the GFP
+ cell fraction. However, in response
to stimulation with 5-fluorouracil, the hematopoietic stem cells of the crossed mice still retained a high level of GFP
expression when it was anticipated the label should be lost when the cells divide. Upon further review, it was determined
that the founder H2B-GFP mice showed spurious expression of the transgene at high levels in the hematopoietic stem cell
population, thus the observed response of hematopoietic stem cells in the double transgenic mice to doxycycline was due
to aberrant expression of the transgene and not the correct tetracycline-regulatable system.
Conclusions: We observed promiscuous expression of the H2B-GFP transgene in the hematopoietic stem cell compartment
of the bone marrow. This leaky expression prohibits the use of this model to study hematopoietic stem cells in vivo and
careful characterization for each organ must be done if this transgenic system is to be used to isolate other prospective
tissue stem cells.
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Introduction
Adult stem cells are characterized by the ability to self-renew to
replenish the stem cell pool and the capacity to differentiate and
generate specialized cell types of their tissue of residence to replace
damaged or lost cells. The study of adult stem cells relies on the
ability to identify and isolate them from the tissue, with the latter
usually requiring multi-color flow cytometry harnessing a
combination of positive and/or negative cell surface markers
which distinguish the stem cell from other cells of the tissue. For
example, mouse hematopoietic stem cells (HSCs) are typically
isolated using some combination of Sca-1
+, c-kit
+, CD150
+ [1] and
lack of expression of markers of mature hematopoietic cells types
such as CD4, CD8, Gr-1, Mac-1, Ter119 and B220 (lineage
negative or Lin
2). Such complex marker combinations make the in
vivo study of stem cells in their niche difficult by immuno-histology.
Another general characteristic of adult stem cells is the state of
quiescence or slow cell turnover under normal physiological
conditions. In general, stem cells have a slow rate of turnover at
steady state to conserve growth potential and prevent genetic
injury during mitosis. This property has been used to identify
putative stem cells in skin [2], kidney [3], cornea [4] and prostate
[5] by BrdU pulse-chase experiments. Recently, a group
developed a transgenic mouse methodology to fluorescently label
slow cycling cells such as prospective stem cells. The transgenic
mice express histone H2B-GFP controlled by a tetracycline-
responsive element (TRE) upstream of a CMV promoter [6]. The
H2B-GFP expression in these mice should be silent in the absence
of a tetracycline transactivator protein (tTA). When the H2B-GFP
mice are crossed to mice harboring a promoter-driven tetracy-
cline-regulatable transactivator protein, H2B-GFP fluorescence is
produced when the tTA binds to the TRE. The H2B–GFP fusion
protein becomes incorporated into nucleosomes without affecting
cell cycle progression [7]. The H2B-GFP fusion protein makes the
fluorescent label very stable and the nuclear localization also
facilitates easier identification of label-retaining cells in histological
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released from the TRE and GFP expression is lost when the cells
divide and H2B-GFP is replaced in nucleosomes by normal
unlabelled histone 2B. Hence only the non-dividing cell popula-
tion will retain H2B-GFP expression over a long period of time in
the presence of doxycycline.
The group that generated the H2B-GFP mice used a keratin 5
promoter-driven tetracycline-regulated transactivator to specifically
label the skin [6]. After a 4-week doxycycline chase, the only GFP
+
cells were in the bulge, the presumptive skin stem cell compartment
[8]. Although the original authors used these mice to study skin stem
cells, these H2B-GFP mice could conceivably be crossed with mice
expressing other tissue-specific promoter-driven tetracycline-regula-
table transactivators to isolate quiescent GFP
+ label-retaining cells
(presumptivetissue stem cells)fromotherorganswhereresident stem
cellshavenotbeenisolatedorforwhichnomarkersforisolationexist
such as pancreas and kidney. Moreover, labeling stem cells in vivo
with a single tag (GFP) would allow the study of stem cell-niche
interactions with more complex immunofluorescent multi-marker
staining. This aspect of stem cell biology has been hampered in the
hematopoietic field by virtue of the multitude of markers required to
identify such a numerically minor cell population of the bone
marrow (HSCs are typically found in the bone marrow at a
frequency of 0.01%). Although one study recently used a somewhat
simplified combination of markers (CD150
+CD48
2CD41
2Lin
2)t o
identify HSCs in histological sections [9], this strategy still required
combining multiple antigens with the same fluorophore and used all
available spectral channels. Even using this strategy leaves few if any
available spectral channels to label sections with markers of
endothelial cells, osteoblasts or bone marrow stroma in combination
with HSCs to study the hematopoietic stem cell niche in vivo.O n eo f
the major advantages to using this H2B-GFP transgenic model is the
potential ability to label quiescent stem cells with a single fluorescent
marker (GFP) thereby freeing up all other spectral channels for co-
staining with markers of other cell types found in the HSC niche.
Because there is no one marker that is uniquely and specifically
expressed by HSCs, we sought to use the H2B-GFP mice to
fluorescently label HSCs in vivo. In the absence of a bone marrow-
specific promoter-driven tetracycline-regulatable transactivator
mouse strain, we crossed H2B-GFP mice to transgenic mice
expressing tTA from a generic CMV promoter (CMV-tTA mice,
referred to from here as TET-off mice since the addition of
doxycycline results in repression of genes under the control of a
TRE). When the progeny of this cross (CMV-tTA-H2B-GFP mice,
referred to from here as TET-GFP mice; Figure 1) were
administered doxycycline in their drinking water, we observed a
decrease in total bone marrow GFP
+ cells over a 12 week treatment
timecourse while approximately 90% of the HSC population
remained GFP
+ after this time. Histologically, GFP
+ cells were most
concentrated at the endosteal surface, one of the proposed HSC
niches [10]. Because of the potential power of this tetracycline-
regulatable system we carefully analyzed all of the parameters before
undertaking a large study. Upon further investigation, it was
discovered thattheH2B-GFPfoundermiceshowedleaky expression
of GFP in the bone marrow, and in particular spurious and high
expression of the transgene in the HSC compartment. These mice
should not show any H2B-GFP expression prior to being crossed to
the TET-off mice because no tTA protein is present to drive GFP
expression from the TRE. This leaky background GFP expression in
the bone marrow of the uncrossed H2B-GFP mice makes them
unsuitable for the purposes of labeling HSCs in vivo. However, the
observation that the H2B-GFP transgene is expressed almost
constitutively by the HSC population is interesting and may warrant
further investigation into the mechanism.
Results
Bone Marrow Response of TET-GFP Mice to Doxycycline
In the system presented in this study, TET-GFP mice should
show a reduction in GFP
+ cells in response to continuous
doxycycline (dox) treatment as the dox causes the tTA to be
released from the TRE and H2B-GFP expression is lost. H2B-
GFP is replaced by normal H2B when the cells divide and hence
only the non-dividing cells (in this case theoretically HSCs) retain
the GFP label long-term. The TET-GFP mice were treated with a
dox timecourse to determine the proportion of the GFP
+ cells in
the bone marrow and HSC compartment over time (Figure 2).
Prior to administration of dox, the GFP
+ fraction of the total bone
marrow ranged from 15–20% (average 16.2%) which was lower
than anticipated when crossing to a generic CMV promoter-
driven tetracycline-regulatable transactivator, although this may
be a function of having both the tTA and H2B-GFP driven by
separate CMV promoters in the same cell. Also the GFP signal
was quite dim when analyzed by flow cytometry although the
GFP
+ population could confidently be identified when compared
to wild type control animals. Regardless, the HSC population of
these mice prior to dox treatment was close to 95% GFP
+. Every
week for 12 weeks of dox treatment, two mice were taken for flow
cytometry analysis (Table 1). As expected, the proportion of GFP
+
cells in the total bone marrow, comprised of cells that are rapidly
turned over, decreased gradually to ,1.6% at 12 weeks while the
proportion of GFP+ cells in the slowly-dividing HSC population
declined only slightly, dropping to only ,85%. The slight
fluctuations in HSC GFP
+ percentage between time-points can
be attributed to variation between individual animals.
It should be noted that although this initial analysis appeared
successful in labeling the HSC population, there was still some
element of background GFP expression in other cell types even at
these long time-points. This could be demonstrated by the fact that
only about 5% of GFP
+Lin
2 cells from TET-GFP mice after
12 weeks of dox treatment also expressed the stem cell markers Sca-
1
+c-Kit
+ indicating that many non-stem cells also retained GFP
expression. This presented an important caveat in that although
almost all HSCs remained GFP
+,n o ta l lG F P
+ cells were HSCs.
Localization of GFP
+ Cells in situ
One of the major purposes of using this fluorescent labeling
strategy was to facilitate the study of HSCs with their niche in vivo.
After 12 weeks of dox treatment, the femurs of TET-GFP micewere
fixed and sectioned tolocalizethe GFP
+ cells. Because we observed a
high level of background autofluorescence in bone sections of wild-
type controls, an anti-GFP antibody was used in conjunction with
H2B-GFP fluorescence to confidently identify the labeled cells of
TET-GFP mice (autofluorescent signals tended to be restricted to
either red or green channels) . While double positive cells (GFP
+/
anti-GFP
+) were observed scattered throughout the bone marrow
(Figure 3), we did find concentrations of these cells at the endosteal
surface of the bone interfacing with the marrow cavity. The
endosteal surface has been proposed as a predominant HSC niche
by numerous studies [10]. However, as discussed above, despite the
fact that almost all phenotypically-defined HSCs were GFP
+ at this
timepoint, not all GFP
+ cells were HSCs. Thus to definitively imply
that the GFP
+ cells in these sections were HSCs, other additional
markers would need to be used (CD150, Sca-1, c-Kit) in
combination, a task made difficult by the lack of filters available
for epifluorescence microscopy. In keeping with the fact that GFP is
not necessarily a good marker of HSCs in the TET-GFP mice
treated with dox, we also found many GFP
+/anti-GFP
+ cells
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necessarily associated with a HSC niche.
Competitive Bone Marrow Transplantation
To test HSC function, GFP
+ and GFP
2 cells were purified from
the bone marrow of TET-GFP mice treated with doxycycline for
12 weeks. No other stem cell markers were in this isolation, which
relied on GFP alone to serve as a marker of HSCs. 200 GFP
+ or
GFP
2 donor cells (CD45.1) were competitively transplanted into
lethally irradiated CD45.2 recipient mice (n=4) along with 200,000
CD45.2 whole bone marrow competitor cells. 12 weeks post-
transplant, peripheral blood was analyzed for donor cell engraft-
ment, GFP fluorescence and lineage contribution (Figure 4). All of
the HSC activity was located in the GFP
+ fraction, although the
chimerism of recipients blood was low (2.84 6 0.87%). This
peripheral blood engraftment was significantly higher (p=0.057)
than mice transplanted with GFP
2 cells (0.27 6 0.05%), in which
donor cells were barely detectable compared to background staining
levels. Donor GFP
+ cells were seen to have multi-lineage potential
with robust contribution seen to myeloid, B cell and T cell
compartments. However, the low level of engraftment suggested
that although the GFP
+ cell fraction was enriched for HSC activity
compared to the GFP- fraction, it still was not a pure HSC
population, an observation consistent with our previous findings.
Another caveat was that the progeny of donor GFP
+ cells in the
peripheral blood were GFP
2 after 12 weeks, which was anticipated
as GFP expression should be lost when the GFP
+ cells divide.
Response to 5-FU
We then attempted to determine if the long-term dox-treated
GFP-labeled cells of TET-GFP mice could respond appropriately
to a given stimulus. A single injection of the pyrimidine analog 5-
FU kills cycling hematopoietic cells and forces the quiescent HSC
population into cycle to repopulate the ablated hematopoietic
system. HSC proliferation proceeds in a time-dependent manner
[11], peaking 5–6 days after injections (in this experiment HSCs
were defined as SP
+Lin
2Sca-1
+ as c-Kit is downregulated on these
cells in response to 5-FU). Therefore, upon stimulation by 5-FU,
the quiescent GFP-labeled HSC population should be forced into
cycle and GFP expression would be lost as the cells divide. 6 days
Figure 1. Schematic representation of transgenic mouse breeding scheme. H2B-GFP mice should not express GFP in the absence of a
tetracycline-regulatable transactivator. When these mice are crossed to mice expressing tTA from a CMV promoter (TET-off mice), the resulting mice
(TET-GFP) express GFP when the tTA binds to the tetracycline responsive element (TRE). When these mice are chased with doxycycline (TET-GFP-DOX)
the doxycycline binds to the tTA complex, dislodging it from the TRE and turning off expression of GFP. GFP expression is lost once the cells divide
therefore only the quiescent cells retain the GFP label long-term.
doi:10.1371/journal.pone.0002357.g001
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GFP mice were still GFP
+, while 13 days after injection the
proportion of GFP
+ HSCs actually increased back up to ,80%
(Figure 5). This result was surprising, as it was expected that some
HSCs would remain in quiescence and hence retain the GFP
+
label, but the majority of HSCs should be stimulated to proliferate
to replace the ablated hematopoietic system and hence would lose
their GFP upon cell division. Moreover, the proportion of GFP
+
cells actually increased from day 6 to day 13 after 5-FU. This
should not occur when these mice are continuously treated with
dox , because once the GFP is lost, it should never be able to be
regained as long as dox is present, and hence the proportion of
GFP
+ HSCs should only continue to decrease.
This result, and the observation that such a high proportion of
HSCs were still GFP
+ after the 12-week dox treatment, conflicted
with data regarding the proportion of HSCs actively proliferating
and cycling at any given point in time [12]. We went back to
analyze the H2B-GFP mice in the absence of the tet-transactivator
Figure 2. Flow cytometric analysis. (A–D) Gating scheme used to identify mouse hematopoietic stem cells which were defined as side population
(A), lineage negative (B), c-Kit
+Sca-1
+ (C). This population was then gated to a Sca-1/GFP plot to identify the proportion of HSCs that were GFP
+. (D)
HSCs from TET-GFP mice prior to administration of doxycycline were 95% GFP
+. (E–F) Proportion of GFP
+ cells in whole bone marrow of TET-GFP mice
prior to dox treatment (E) and after 12 weeks of dox treatment (F). The percentage of GFP
+ cells in whole bone marrow decreased in response to dox.
(G) HSCs from TET-GFP mice after 12 weeks treatment with dox were still over 85% GFP
+. (H) However, after 12 weeks of dox treatment not all GFP
+
cells from TET-GFP mice were HSCs as only 5% of GFP
+Lin
2 cells were Sca-1
+c-Kit
+. The percentage of GFP
+ whole bone marrow cells from TET-GFP
mice decreased in response to dox (J) while the majority of HSCs remained GFP
+ (K).
doi:10.1371/journal.pone.0002357.g002
Table 1. Proportion of GFP
+ cells in whole bone marrow and hematopoietic stem cell population from TET-GFP mice treated with
doxycycline.
Week 0 Week 1 Week 2 Week 3 Week 4 Week 6 Week 8 Week 12
%BM GFP+ 16.2 12.0 8.2 6.4 6.2 4.1 3.7 1.6
%HSC GFP+ 94.9 91.4 87.7 82.7 90.6 88.5 87.1 87.6
doi:10.1371/journal.pone.0002357.t001
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mice express no tetracycline-regulated transactivator, and thus
should not express GFP, we found that the HSCs of this mouse
strain were in fact .85% GFP
+. In addition, it should be noted
that even in peripheral blood and whole bone marrow, we could
detect a low level of GFP expression. Therefore this strain displays
promiscuous expression of H2B-GFP in certain hematopoietic cell
types, but in particular the HSC population. Although it did
appear that the majority of bone marrow from TET-GFP mice did
respond appropriately in response to doxycycline (gradual
reduction in GFP
+ cells over time), GFP
+ cells could still be
detected in whole bone marrow at a frequency of about 1.6% after
12 weeks of dox. Although it was anticipated that some quiescent
HSCs, would still be labeled after this length of time, the majority
of GFP
+ cells must be attributed to leaky expression of the
transgene from the H2B-GFP strain. Of particular note, the
transgene appeared to be extremely active in HSCs. For example,
in the TET-GFP mice after 12 weeks dox treatment, approxi-
mately 3 out of every 200 bone marrow cells were GFP
+, but from
the same animal, approximately 170 out of every 200 HSCs were
GFP
+. Although GFP
+ cells were enriched in the HSCs, not all
GFP
+ cells were HSCs, as the frequency of HSCs in bone marrow
is about 0.01% compared to a frequency of GFP
+ cell occurrence
at 1.6%. Moreover, the HSC response of the H2B-GFP mice to 5-
FU was exactly the same as the dox-treated TET-GFP mice.
Taken together, these results indicate that any HSC response in
the TET-GFP mice was not due to the appropriate tetracycline-
regulated system, but rather spurious expression of the transgene
specifically in the HSC population.
Discussion
The ability to fluorescently label a quiescent (potential stem cell)
population in vivo using a transgenic tetracycline-regulatable
system is potentially a very powerful tool for the study of adult
stem cells. It presents many advantages over the traditional BrdU
pulse-chase methodology such as the ability to isolate viable long-
term label-retaining cells by flow cytometry for in vitro or
transplantation assays. The group that developed the system
originally used a very elegant system to identify the bulge cells of
the skin as the quiescent GFP label-retaining population in this
organ [6] and these cells have subsequently been characterized as
skin stem cells [8].
We sought to use a similar model to fluorescently label HSCs in
vivo to study niche interactions in the bone marrow. While our
initial results were encouraging in that we appeared to retain GFP
label primarily in the HSC population in response to long-term
doxycycline treatment, labeled cells appeared to localize to the
endosteal niche in bone sections, and competitive transplantation
showed that functional HSC activity was restricted to the GFP
+
cell fraction, it was later discovered that retention of GFP
expression in the double transgenic TET-GFP mice was in fact
due to tet-transactivator-independent expression of the H2B-GFP
mouse transgene. Notably, the transgene was especially activated
in the HSC population, which made any results obtained from the
dox-treated TET-GFP mice uninterpretable.
One could argue that the H2B-GFP mice themselves might be
useful to study HSCs in vivo because almost all of the HSCs are
GFP
+. But these mice also show expression of GFP in other bone
marrow cells (in fact these mice were routinely genotypyed by flow
cytometry of the peripheral blood where we observed that ,5% of
the nucleated blood cells were GFP
+), so while almost all HSCs are
GFP
+ not every GFP
+ cell is a HSC. We observed an average of
1.8% of GFP
+ cells in whole bone marrow from these animals
(data not shown), which is almost identical to the proportion of
GFP
+ cells in the bone marrow of TET-GFP mice treated with
dox for 12 weeks (1.6%). This again suggests that the long-term
GFP-labeled cells from the TET-GFP mice were due to a leaky
background expression from the H2B-GFP strain and not the
appropriate tetracycline-regulated response. The H2B-GFP trans-
gene was particularly active in the HSC compartment of the H2B-
GFP mice, and in fact, if GFP was used as the only marker for
purification of cells from the bone marrow, it would enrich for
HSC activity approximately 48-fold compared to whole bone
marrow (given 1.8% of whole bone marrow cells are GFP
+, 85%
of HSCs are GFP
+ and assuming a normal HSC frequency in
bone marrow of ,0.01%). To use the GFP
+ HSCs from the H2B-
GFP mice to localize HSC within their bone marrow niche, the
problem of leaky H2B-GFP expression in non-HSCs could
potentially be circumvented by purifying HSCs from these mice
and transplanting them into a wild-type recipient. But the HSCs
are then exposed to a strong selective pressure and may not home
to their normal niche or behave in their typical fashion. This also
may not solve the problem since the transplanted HSCs will
generate progenitors which may still express the transgene. Also
one of the aims of using this system was to locate HSCs in vivo by
labeling with only one color (GFP) for immunofluorescence
Figure 3. Bone section of a TET-GFP mouse treated with
doxycycline for 12 weeks. An anti-GFP antibody was used in
combination to correctly identify GFP
+ cells due to autofluorescence in
the sections. In the merged image, the white dashed line indicates the
endosteal surface at the bone/bone marrow interface. Concentrations
of GFP
+/anti-GFP
+ cells from TET-GFP were witnessed at the endosteal
surface, one of the proposed HSC niches. The yellow box in the merged
image is magnified below to more clearly show a cluster of double
positive cells.
doi:10.1371/journal.pone.0002357.g003
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other markers to study HSC-niche interactions with endothelial
cells, osteoblasts or other cell types. The fact that not all GFP
+ cells
were HSCs in H2B-GFP and TET-GFP mice treated with dox for
12 weeks again limits the usefulness of this system as multiple
markers (i.e. Sca-1, c-kit, CD150) would need to be used to
correctly identify HSCs thereby limiting the number of available
colors for other cell types.
The reason for this spurious GFP expression specifically in the
HSC population is unclear, but somewhat interesting. The vast
majority of bone marrow cell types showed a tight regulation of
GFP in response to dox treatment which poses the question of why
the HSC population relatively specifically showed aberrant GFP
expression in the absence of the tTA protein. Perhaps the
transgene was integrated into a genomic region that is permissive
for expression in HSCs or a locus that exhibits high transcriptional
activity. Another explanation could be that, as suggested by recent
studies, HSCs and other stem cells have a more ‘‘open’’ chromatin
structure to facilitate rapid gene transcription for multiple cell
lineage differentiation programs with chromatin becoming more
closed as differentiation occurs [13]. This could make tetracycline-
regulated transgene expression not as tight in HSCs compared to
differentiated cells which have a more rigidly controlled
transcriptional program. In response to 5-FU, the proportion of
GFP
+ HSCs from H2B-GFP and TET-GFP mice treated with dox
decreased from 85% at day 0 to ,55% at day 6, but then
increased back up to ,80% by day 13. So there was some
response of the transgene in the HSCs of these animals. These
results may suggest that the H2B-GFP transgene is integrated in a
locus that becomes transcriptionally repressed during HSC
activation and proliferation (day 6 post 5-FU), but then resumes
transcriptional activity upon return of HSCs to a more stable,
quiescent state (day 13 post 5-FU). An alternative explanation for
this may be that for some reason, the GFP
2 HSCs might have
died or differentiated such that the GFP
+ cells became a higher
proportion of the total HSC population.
Another possibility is that H2B-GFP fusion protein itself affects
cell behavior. Although the fusion protein enables sensitive
analysis of chromosome dynamics in living mammalian cells in
vitro [7], there is little evidence to suggest it has no impact on cell
function in vivo. The original study using this methodology to label
skin stem cells did not show any adverse effects from the H2B-GFP
transgene [6], it has not been conclusively shown that H2B-GFP
does not affect the gene expression profile or cell fate decisions in
Figure 4. Competitive transplantation of GFP
+ and GFP
2 cells from TET-GFP mice treated with doxycycline for 12 weeks. Analysis of
peripheral blood of mice transplanted with GFP
2 (A) and GFP
+ (B) cells 12 weeks post-transplant showed that only cells from the GFP
+ fraction were
able to contribute to hematopoiesis of recipient mice. (C) Gating of donor CD45.1 cells from GFP
+ cell transplant recipients showed that they could
contribute to all major lineages of the peripheral blood (B cells, T cells, myeloid cells). (D) Average peripheral blood engraftment of mice transplanted
with either GFP
+ or GFP
2 cells from TET-GFP mice treated with doxycycline for 12 weeks (n=4). GFP
+ donor cells showed significantly higher
engraftment levels with any engraftment of GFP
2 donor cells being likely artefactual.
doi:10.1371/journal.pone.0002357.g004
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protein is composed of the 126 amino acid H2B histone fused to
the 239 amino acid GFP via a six amino acid linker. The presence
of the GFP moiety, which is almost twice the molecular weight of
H2B, makes the chimeric H2B-GFP much bulkier than the wild
type histone protein and it is possible that the presence of this extra
protein in nucleosome core particles does affect the fine structure
of the chromatin. The incorporation of H2B-GFP into chromatin
may affect gene expression profile and cell fate commitments via
multiple mechanisms including effects on nucleosome structure,
chromatin structure, histone code, epigenetic regulation of gene
expression, asymmetric cell division and potential ‘‘leakiness’’ of
the doxycycline-inducible system itself.
Chromatin structure has been shown to be crucial to normal
HSC function and any disruption to the normal architecture by
inclusion of H2B-GFP could have deleterious effects. While the
inner core of the nucleosome is very stable, it has been shown H2B
on the surface of active nucleosomes exchanges continually [14],
thus permitting cell lineage visualization by H2B-GFP in
transgenic animals, but also allowing for the possible perturbation
of HSC function by replacement of wild type H2B with H2B-GFP.
Furthermore, ubiquitination of H2B affects the methylation status
of H3 [15], thus substitution of H2B-GFP for wild type H2B may
alter the epigenetic histone code in these transgenic animals.
Epigenetic modifications have been shown to serve as an
important mechanism that controls HSC multipotency and cell
fate decisions and several observations suggest that epigenetic
modifications (including histone modifications) are present at
lineage gene-specific loci in HSCs [16]. The molecular processes
governing hematopoiesis involve the interplay between lineage-
specific transcription factors and a series of epigenetic tags,
including DNA methylation and covalent histone tail modifica-
tions such as acetylation, methylation phosphorylation, SUMOy-
lation and ubiquitylation. These post-transcriptional modifica-
tions, which collectively constitute the ‘‘histone code’’, are capable
of affecting chromatin structure and gene transcription and are
catalyzed by opposing families of enzymes allowing the develop-
mental potential of hematopoietic stem cells to be dynamically
regulated [17]. Several genes that are involved in epigenetic
modifications are crucial to HSC function, such as the polycomb
group gene Bmi1 which has been shown to be critical for long-
term maintenance of HSCs in humans [18] and mice [19].
Substitution for H2B-GFP for wild type H2B in these transgenic
animals may alter any number of these processes which would
then have profound effects on normal HSC function in vivo. Also,
while reporter genes have been extensively used to monitor a wide
Figure 5. Hematopoietic stem cell response of wild-type, dox-treated TET-GFP and H2B-GFP mice to 5-FU. The HSC response of TET-
GFP mice + dox (middle panels) and H2B-GFP mice lacking the tetracycline-regulated tTA (bottom panels) are identical. Note in particular the level of
GFP expression at day 13 in all three genotypes (far right column), the proportion of GFP
+ HSCs actually increased in TET-GFP mice +dox and H2B-GFP
from day 6 to day 13.
doi:10.1371/journal.pone.0002357.g005
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of the reporter gene may alter the biological activity of certain cells
[20], a phenomenon which has been observed in the hematopoi-
etic system [21].
In addition, the inducibility of doxycycline-regulated gene
expression in various tissues and cell types strongly depends on the
appropriate choice of tetracycline-responsive promoter [22]. Cur-
rently available drug-inducible model systems usually rely on the
transactivation of artificial promoters by chimeric transcription
factors. Although this most often results in high-level transgene
expression,the use ofnativecellularpromotersorenhancer elements
would be preferable in many circumstances. Moreover, the systems
in their present versions are limited by leakiness that results from
non-specific binding of the transactivator to the synthetic promoter
in the uninduced state. Recent studies have described highly
versatile, single vector lentiviral tools that allow for conditional
transgene expression from any ubiquitous or tissue-specific promoter
as well as for conditional RNA interference [23] and transgenic mice
produced by these methods may more allow more accurate lineage
tracing than described with the system in this study. Also, the
usefulness of GFP as a cell lineage marker has been questioned as
potential limitations were highlighted in a recent report comparing
three mouse strains in which GFP is considered ‘‘ubiquitously
expressed’’. This study found considerable variation in GFP
expression within and between GFP transgenic strains and none of
the strains gave truly ubiquitous GFP expression [24]. A detailed
analysis of GFP expression in one’s tissue of interest must guide the
choice of reporter mouse strain when GFP is used as a marker of cell
lineage or donor origin.
This technology potentially is a powerful tool for studying
potential adult stem cells, or other slow cycling cells, from organs
for which few other markers exist, and thus there are currently
many efforts to do so using the H2B-GFP mice. However, the
studies presented here demonstrate the potential for leaky GFP
expression which could prohibit the ability to obtain meaningful
data from such studies. The utility of the system is likely to be
dependent on several factors, including the mouse strain
background, as well as the tissue of study. The effectiveness of
the particular promoter-driven tetracycline-regulatable transacti-
vator the H2B-GFP mice are crossed with is likely to have a major
impact. It is possible that tet-transactivator transgenes other than
the CMV tet-transactivator used here would result in higher
expression of the GFP, such that the tet-transactivator-dependent
GFP could be distinguished by flow cytometry from the spurious
GFP expression demonstrated here that is ,1 log above
background. However, this would have to be clearly demonstrated
with appropriate controls, including analysis of GFP expression in
the population of interest in mice bearing the H2B-GFP transgene
alone. Even so, the two types of GFP expression would be unlikely
to be able to be distinguished in tissue sections, since fluorescence
levels are far less easily quantified by microscopy. It is likely that
generation of new founder lines of H2B-GFP transgenic mice will
be necessary for the study of slow-cycling cells in the hematopoietic
system. Thus, this study serves as a cautionary tale for use of this
potentially useful transgenic mouse line, particularly in the
hematopoietic system.
Materials and Methods
Mice and Genotyping
H2B-GFP mice were obtained from the Fuchs laboratory (The
Rockefeller University, New York). CMV-tTA (TET-off) mice
were obtained from Jackson labs (Bar Harbor, Maine). H2B-GFP
mice and TET-GFP mice were genotyped by flow cytometric
analysis of the peripheral blood with GFP
+ mice displaying ,5%
GFP
+ nucleated blood cells. DNA was extracted from tail tips of
TET-off and TET-GFP mice using the DirectPCR Lysis Reagent
(Viagen Biotech) system and were genotyped with the following
PCR primers; CMV-tTA-forward CATGTCCAGATCGAAAT-
CGTC, CMV-tTA-reverse CGCTGTGGGCATTTTACTT-
TAG. TET-GFP mice were administered doxycycline (2 mg/
mL; Sigma) in drinking water supplemented with 5% sucrose and
protected from light. The water was changed every three days to
ensure activity of doxycycline. All mice were housed in a specific
pathogen-free barrier and fed autoclaved acidified water and
mouse chow ad libitum were used. All animal procedures were
conducted in accordance with the Baylor College of Medicine
(Houston, Texas, USA) institutional guidelines.
Flow Cytometry
For analysis of HSCs, whole bone marrow was collected from
the femurs and tibias of mice. Cells were resuspended at 1610
6/
mL and stained with Hoechst 33342 at 37uC for 90 minutes and
subsequently stained with Pe-Cy5 conjugated antibodies against
mature lineage markers (Gr-1, Mac-1, CD4, CD8, B220 and
Ter119; all from eBioscience) as well as c-Kit-PE and Sca-1-APC
(both from BD Pharmingen). HSCs were defined as cells
displaying the side population (SP) phenotype, c-Kit
+Lin
-Sca-1
+
(SP
KLS). Flow cytometric analysis was performed on a triple laser
MoFlo (DakoCytomation).
Figure 6. Hematopoietic stem cells of wild-type, dox-treated
TET-GFP and uncrossed H2B-GFP mice lacking the tetracycline-
regulated transactivator. The HSCs of H2B-GFP mice show strong
expression of GFP even in the absence of the tTA.
doi:10.1371/journal.pone.0002357.g006
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Femurs were dissected and fixed by immersion in 4% PFA/PBS
for three days followed by three days in 30% sucrose. Bones were
mounted in OCT (Tissue-Tek) and snap frozen. Sections were cut
on a cryostat and transferred to slides with the Cryojane tape
transfer system (Instrumedics). Slides were air-dried for 2 hours
and stored at 280uC until use. For immunofluorescence, slides
were washed in PBS, permeabilized for 10 minutes in PBTX and
blocked for 30 minutes in PBS+1% BSA. Slides were incubated in
PBS+1% BSA with rabbit anti-GFP primary antibody (1:200
dilution; Sigma) for 1 hour at room temperature. Slides were then
washed for 30 minutes and then incubated with anti-rabbit Alexa-
594 secondary antibody (1:500 dilution; Molecular Probes) for
1 hour at room temperature. Slides were mounted in Vecta-
shield+DAPI (Vector Laboratories) and images captured on a
Zeiss Axioplan 2 microscope equipped with Photometrics Cool-
snap HQ camera.
Competitive Bone Marrow Transplantation
Following a split dose of 10.5 Gy of whole body irradiation,
C57Bl/6-CD45.2 recipients (n=4 for each group) were trans-
planted via retro-orbital intravenous injection with 200 GFP
+ or
GFP
2 bone marrow cells from C57Bl/6-CD45.1 TET-GFP mice
treated with doxycycline for 12 weeks. Donor cells were competed
against 200,000 CD45.2 whole bone marrow cells. Recipient mice
were analyzed for donor cell engraftment 12 weeks post-
transplant. Following red blood cell lysis, peripheral blood samples
were incubated with CD45.1-APC (BD Biosciences), CD4-Pacific
Blue, CD8-Pacific Blue, B220-Pacific Blue, B220-PeCy7, Mac-1-
PeCy7 and Gr-1-PE antibodies (all eBioscience). Samples were
analyzed on a LSRII (BD) flow cytometer.
HSC Stimulation by 5-Fluoruracil
For 5-Fluorouracil (5-FU) treatment, mice were injected
intraperitoneally with a single dose of 5-FU (150 mg/kg body
weight; Sigma) and sacrificed 6 or 13 days after injection for HSC
analysis.
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